Arcutis Biotherapeutics Inc (ARQT)

Arcutis reported its Q1 2026 financial results on May 6, 2026, with net product revenues of $105.4 million, a 65% increase compared to Q1 2025, but a 17% sequential decline from Q4 2025. The company maintained its full-year 2026 revenue guidance of $480 million to $495 million. Arcutis submitted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to the FDA to expand its indication for atopic dermatitis to infants aged 3 to 24 months. A PDUFA action for pediatric psoriasis (ZORYVE cream 0.3%) is anticipated on June 29, 2026. The stock price of ARQT has decreased by 27.1% since the beginning of 2026.

Arcutis Biotherapeutics experiences demand seasonality for its products, particularly in the first quarter of the year, due to factors such as patient deductible resets, elevated co-pay utilization, annual insurance transitions, and the pull-forward of refills into the fourth quarter of the previous year. This seasonal pattern was further amplified in Q1 2026 by severe weather events across the United States. The company anticipates a return to robust quarter-on-quarter demand growth following the first quarter.

Arcutis Biotherapeutics is a commercial-stage medical dermatology and biopharmaceutical company focused on immune-mediated dermatological diseases. The company develops topical therapies, with its primary product portfolio built around ZORYVE (roflumilast), a phosphodiesterase type 4 (PDE4) inhibitor. ZORYVE is available in various cream formulations and a topical foam, indicated for the treatment of mild to moderate atopic dermatitis in pediatric patients, plaque psoriasis, and seborrheic dermatitis. Arcutis also has a pipeline candidate, ARQ-234, a biologic being developed for atopic dermatitis, which has initiated Phase 1 studies.

Arcutis Biotherapeutics' corporate office is located in Westlake Village, California, United States. The company's product revenue growth has been driven by demand in the United States and Canada. Strategic licensing agreements have expanded Arcutis' global footprint, particularly into Asian markets.

Arcutis Biotherapeutics has a positive brand reputation, particularly concerning its flagship product, ZORYVE, which is the number one prescribed branded topical therapy across its approved indications. ZORYVE cream received a strong recommendation with high certainty of clinical evidence in the American Academy of Dermatology's clinical practice guidelines for the management of pediatric atopic dermatitis.

Arcutis Biotherapeutics has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 32.75% of the company's stock is owned by Institutional Investors, 9.18% by Insiders, and 58.07% by Public Companies and Individual Investors. Major institutional owners include Suvretta Capital Management, Llc, Frazier Life Sciences Management, L.P., BlackRock, Inc., Rubric Capital Management LP, Vanguard Group Inc, Jennison Associates Llc, Polar Capital Holdings Plc, State Street Corp, Gilder Gagnon Howe & Co Llc, and Morgan Stanley. Patrick Heron is noted as owning the most shares among individual investors.